APL Bioengineering

APL Bioengineering is a fully open-access journal published by AIP Publishing, launched in 2017 to cover research where biology meets physics and engineering, with a 2025 Journal Impact Factor of 4.9.「APL 生物工程」由（AIP Publishing）出版，2017 年创刊，为完全开放获取期刊，专注生物学与物理学、工程学的交叉研究，2025 年期刊影响因子为 4.9。

Scope

• Biofabrication and bioprinting form one core area, covering printed scaffolds, organ models and additive manufacturing of living constructs.生物制造与生物打印是核心方向之一，涵盖打印支架、器官模型与活体构建体的增材制造。
• Biomedical materials, sensors and imaging are grouped together, from implantable materials to diagnostic devices and imaging probes.生物医学材料、传感器与成像归为一组，从可植入材料到诊断器件与成像探针。
• Engineered living systems and cell or tissue engineering cover the design of cells, tissues and organoids with controlled function.工程化生命系统与细胞、组织工程，涉及具有可控功能的细胞、组织与类器官设计。
• Regenerative medicine, including stem cell engineering, biomaterial scaffolds and tissue-integrating hydrogels, is a standing theme.再生医学为常设主题，包括干细胞工程、生物材料支架与组织整合水凝胶。
• Molecular, cell and tissue biomechanics address how mechanical forces shape cell fate, tissue growth and disease progression.分子、细胞与组织生物力学，研究机械力如何塑造细胞命运、组织生长与疾病进程。
• Systems and computational biology are in scope, and the journal explicitly welcomes artificial intelligence and machine learning applied to any of its topical areas.系统生物学与计算生物学在范围之内，刊物明确欢迎人工智能与机器学习应用于上述任一方向。
• Computational work must be validated experimentally, so predictions of genes, pathways or candidate therapeutics need evidence of biological or engineering relevance.计算工作须经实验验证，对基因、通路或候选疗法的预测需给出生物学或工程学意义的证据。

History

• The first volume appeared in 2017, with issue 1 carrying the launch editorial by editor-in-chief Justin Cooper-White.首卷于 2017 年出版，第 1 卷第 1 期载有主编（Justin Cooper-White）撰写的创刊社论。^[1]
• AIP Publishing, the publishing arm of the American Institute of Physics, has issued the journal since its launch.该刊由（American Institute of Physics）的出版部门（AIP Publishing）出版，自创刊起未易主。
• It was gold open access from the first issue, with articles under a CC BY licence and costs met by an article processing charge rather than subscriptions.自首期起即为金色开放获取，文章采用（CC BY）许可，费用由文章处理费承担而非订阅。
• The journal is online only, identified by ISSN 2473-2877 and CODEN ABPID9, and appears in four issues a year, reaching Volume 10 in 2026.刊物仅在线出版，标识为（ISSN 2473-2877）与（CODEN ABPID9），每年四期，2026 年出至第 10 卷。
• Output has stayed close to one hundred research items a year, with 103 articles published in 2025 and 603 DOIs deposited in total.年发文量保持在百篇左右，2025 年发表 103 篇，累计登记（DOI）603 个。
• Its 2025 Journal Impact Factor is 4.9 with a five-year value of 5.7, and Scopus gives a CiteScore of 6.6, an SJR of 1.099 and an h-index of 47.2025 年期刊影响因子为 4.9，五年影响因子 5.7，（Scopus）给出的（CiteScore）为 6.6，（SJR）为 1.099，（h 指数）为 47。

Editors

• Justin Cooper-White, professor at the University of Queensland, is Editor-in-Chief and works on tissue engineering, biomaterials and regenerative medicine.（Justin Cooper-White）为主编，任（University of Queensland）教授，研究组织工程、生物材料与再生医学。
• Five associate editors handle the field, among them Liming Bian at the South China University of Technology, Adam Engler at the University of California, San Diego, and Arianna Menciassi at Scuola Superiore Sant'Anna.五位副编辑分工负责各方向，包括（South China University of Technology）的（Liming Bian）、（University of California，San Diego）的（Adam Engler）与（Scuola Superiore Sant'Anna）的（Arianna Menciassi）。
• Two independent referees are normally invited, with additional reviews where an editor judges it necessary, and decisions usually follow one or two rounds.通常邀请两位独立审稿人，编辑认为必要时增补评审，一般经一到两轮作出决定。
• Reviewers are anonymous to authors, and accepted formats are articles, reviews, perspectives, comments and errata.审稿人对作者匿名，接受的文章类型包括研究论文、综述、观点、评论与勘误。
• In 2025 the average time to first decision was 24 days, to acceptance 134 days and to publication 158 days.2025 年平均首次决定时间为 24 天，接受到录用 134 天，录用到发表 158 天。
• Rejected authors may appeal through the submission site with a revised manuscript and a one-page case, and editors normally rule within one to two weeks.被拒作者可经投稿系统申诉，附修改稿与一页以内的理由，编辑通常在一到两周内裁定。